Loss of E-cadherin Enhances IGF1–IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors
Abstract
Purpose: Insulin-like growth factor 1 (IGF1) signaling regulates breast cancer initiation and progression and associated cancer phenotypes. We previously identified E-cadherin (CDH1) as a repressor of IGF1 signaling and in this study examined how loss of E-cadherin affects IGF1R signaling and response to anti-IGF1R/insulin receptor (InsR) therapies in breast cancer.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 15, 2018
- Source ID
- 10.1158/1078-0432.ccr-18-0279
Entities
People
- Adrian V Lee
- Alison M. Nagle
- Britta M. Jacobsen
- David N. Boone
- Jennifer M Atkinson
- Julie A. Scott
- Justin Kehm
- Kara Burlbaugh
- Kevin M Levine
- Nilgun Tasdemir
- Steffi Oesterreich
- Tiffany A. Katz
Organizations
- Baylor College of Medicine
- National Cancer Institute
- The Breast Cancer Research Foundation
- United States Department of Defense
- University of Colorado
- University of Pittsburgh